{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:06:47Z","timestamp":1784074007669,"version":"3.55.0"},"reference-count":56,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG079113"],"award-info":[{"award-number":["R01AG079113"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG097158"],"award-info":[{"award-number":["P30AG097158"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG028747"],"award-info":[{"award-number":["P30AG028747"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030098","name":"Montgomery County","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030098","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Maryland Strategic Partnership"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Osteoanabolic therapy for osteoporosis should be followed by antiresorptive treatment (\u201cconsolidation\u201d) to preserve bone mass. Although osteoanabolic therapy is increasingly endorsed for primary fracture prevention, real-world implementation of consolidation remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess patterns and predictors of timely consolidation after osteoanabolic therapy for primary fracture prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged \u226550 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initiation of an antiresorptive medication within 3 months after osteoanabolic therapy. Secondary outcomes included delayed consolidation (initiation &amp;gt;3 months after completion), osteoanabolic restart following a treatment gap, and no consolidation therapy. We further distinguished participants who completed the full osteoanabolic course, defined as \u226512 months for romosozumab and \u226518 months for teriparatide or abaloparatide. Multivariable logistic regression models were used to identify predictors of consolidation patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 15 389 patients (mean age 70.6 years; 89% women; 85% White), 30% completed osteoanabolic therapy (median, 12.9 months for romosozumab; 23.4 months for teriparatide\/abaloparatide). Overall, 25% had timely consolidation, 24% delayed consolidation, 12% restarted osteoanabolics, and 40% had no consolidation; only 12% completed therapy with timely consolidation. Timely consolidation was more likely with endocrinology (OR 1.31; 95% CI, 1.17-1.48) or rheumatology (OR 1.45; 1.30-1.62) vs primary care, and less likely among patients aged 50-64 years (OR 0.67; 0.58-0.77) vs 65-74, those enrolled in Medicare Advantage (OR 0.85; 0.74-0.98) vs traditional Medicare, or those recently hospitalized (OR 0.88; 0.80-0.97). Odds increased over time (OR 4.27; 3.63-5.05 for 2021 vs 2011 starts).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Only 1 in 4 patients received timely consolidation therapy after osteoanabolic treatment, and 1 in 8 completed the full sequence. Strategies to improve consolidation in primary fracture prevention are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag092","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:34:02Z","timestamp":1772541242000},"page":"2320-2331","source":"Crossref","is-referenced-by-count":1,"title":["Timeliness of antiresorptive consolidation after anabolic therapy for primary fracture prevention: A US cohort study"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-1907","authenticated-orcid":false,"given":"Sanaa","family":"Badour","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida , Gainesville, FL 32608 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G","family":"McCoy","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, & Nutrition, Department of Medicine, University of Maryland School of Medicine , Baltimore, MD 21201 ,","place":["USA"]},{"name":"University of Maryland Institute for Health Computing , North Bethesda, MD 21201 ,","place":["USA"]},{"name":"Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine , Baltimore, MD 21201 ,","place":["USA"]},{"name":"OptumLabs , Eden Prairie, MN 55344 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Takagi","sequence":"additional","affiliation":[{"name":"OptumLabs , Eden Prairie, MN 55344 ,","place":["USA"]},{"name":"Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester , Minnesota, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander O","family":"Everhart","sequence":"additional","affiliation":[{"name":"Division of General Medicine and Geriatrics, John T. Milliken Department of Medicine, Washington University School of Medicine in St.Louis , St. Louis, MO 63130 ,","place":["USA"]},{"name":"Center for Advancing Health Services, Policy & Economics Research, Washington University in St.Louis , St. Louis, MO 63130 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Parimi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, & Nutrition, Department of Medicine, University of Maryland School of Medicine , Baltimore, MD 21201 ,","place":["USA"]},{"name":"Division of Endocrinology, Baltimore Veterans Affairs Medical Center , Baltimore, MD 21201 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-3622","authenticated-orcid":false,"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine , New Haven, CT 22903 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-1982","authenticated-orcid":false,"given":"Pinar","family":"Karaca-Mandic","sequence":"additional","affiliation":[{"name":"Department of Finance, Carlson School of Management, University of Minnesota , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Wermers","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford J","family":"Rosen","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine, MaineHealth Institute for Research , Scarborough, ME 04074 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-1745","authenticated-orcid":false,"given":"Juan P","family":"Brito","sequence":"additional","affiliation":[{"name":"Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester , Minnesota, MN 55905 ,","place":["USA"]},{"name":"Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"1","key":"2026071419580404900_dgag092-B1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"2026071419580404900_dgag092-B2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0002-9343(91)90512-V","article-title":"Consensus development conference: prophylaxis and treatment of osteoporosis","volume":"90","author":"Christiansen","year":"1991","journal-title":"Am J Med"},{"issue":"4","key":"2026071419580404900_dgag092-B3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jbmr.2393","article-title":"Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study","volume":"30","author":"Bliuc","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026071419580404900_dgag092-B4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ageing\/afu123","article-title":"Admission for osteoporotic pelvic fractures and predictors of length of hospital stay, mortality and loss of independence","volume":"44","author":"Marrinan","year":"2015","journal-title":"Age Ageing"},{"issue":"8","key":"2026071419580404900_dgag092-B5","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419580404900_dgag092-B6","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419580404900_dgag092-B7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.amjmed.2024.02.012","article-title":"Reconsidering the benefits of osteoporosis treatment: the case of bisphosphonates","volume":"137","author":"Goodman","year":"2024","journal-title":"Am J Med"},{"issue":"6","key":"2026071419580404900_dgag092-B8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jama.2024.27154","article-title":"Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement","volume":"333","author":"Nicholson","year":"2025","journal-title":"JAMA"},{"issue":"9","key":"2026071419580404900_dgag092-B9","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/bph.15024","article-title":"Overview of treatment approaches to osteoporosis","volume":"178","author":"Langdahl","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"10117","key":"2026071419580404900_dgag092-B10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"15","key":"2026071419580404900_dgag092-B11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026071419580404900_dgag092-B12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419580404900_dgag092-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"5","key":"2026071419580404900_dgag092-B14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","article-title":"Treatment sequence for osteoporosis","volume":"30","author":"Cosman","year":"2024","journal-title":"Endocr Pract"},{"issue":"5","key":"2026071419580404900_dgag092-B15","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419580404900_dgag092-B16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"issue":"8","key":"2026071419580404900_dgag092-B17","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419580404900_dgag092-B18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"2026071419580404900_dgag092-B19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026071419580404900_dgag092-B20","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9999","key":"2026071419580404900_dgag092-B21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch Study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"2026071419580404900_dgag092-B22","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026071419580404900_dgag092-B23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff"},{"issue":"8","key":"2026071419580404900_dgag092-B24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9","key":"2026071419580404900_dgag092-B25","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1210\/clinem\/dgae840","article-title":"Trends in osteoporosis drug therapy receipt among commercial and Medicare Advantage enrollees in the United States, 2011-2022","volume":"110","author":"Everhart","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419580404900_dgag092-B26","doi-asserted-by":"crossref","unstructured":"Badour S . Timeliness of antiresorptive consolidation after anabolic therapy for primary fracture prevention: a U.S. cohort study: supplement. Mendeley Data. 23 February 2026. Accessed 25 February 2026. 10.17632\/M6FWP2R7J3","DOI":"10.1210\/clinem\/dgag092"},{"key":"2026071419580404900_dgag092-B27","doi-asserted-by":"crossref","DOI":"10.4324\/9780203771587","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"issue":"25","key":"2026071419580404900_dgag092-B28","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2026071419580404900_dgag092-B29","author":"Saul"},{"issue":"10","key":"2026071419580404900_dgag092-B30","doi-asserted-by":"crossref","first-page":"e10800","DOI":"10.1002\/jbm4.10800","article-title":"Anabolic and antiresorptive osteoporosis treatment: trends, costs, and sequence in a commercially insured population, 2003\u20132021","volume":"7","author":"Wadhwa","year":"2023","journal-title":"JBMR Plus"},{"issue":"12","key":"2026071419580404900_dgag092-B31","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/jbmr.4439","article-title":"Patterns of teriparatide and sequential antiresorptive agent treatment among elderly female medicare beneficiaries","volume":"36","author":"Liu","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"19","key":"2026071419580404900_dgag092-B32","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"2026071419580404900_dgag092-B33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3949\/ccjm.88a.21011","article-title":"Teriparatide: label changes and identifying patients for long-term use","volume":"88","author":"Miller","year":"2021","journal-title":"Cleve Clin J Med"},{"key":"2026071419580404900_dgag092-B34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","article-title":"Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies","volume":"116","author":"Langdahl","year":"2018","journal-title":"Bone"},{"issue":"4","key":"2026071419580404900_dgag092-B35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jbmr.4243","article-title":"Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis","volume":"36","author":"Dempster","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026071419580404900_dgag092-B36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"2026071419580404900_dgag092-B37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2026071419580404900_dgag092-B38","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419580404900_dgag092-B39","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071419580404900_dgag092-B40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11657-022-01110-z","article-title":"A retrospective observational study of osteoporosis management after a fragility fracture in primary care","volume":"17","author":"Bell","year":"2022","journal-title":"Arch Osteoporos"},{"issue":"1","key":"2026071419580404900_dgag092-B41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11657-023-01283-1","article-title":"Osteoporosis management by primary care physicians in Singapore: a survey on osteoporosis guidelines utilisation and barriers to care","volume":"18","author":"Choong","year":"2023","journal-title":"Arch Osteoporos"},{"issue":"2","key":"2026071419580404900_dgag092-B42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026071419580404900_dgag092-B43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2106\/JBJS.23.00272","article-title":"Impact of teriparatide on complications and patient-reported outcomes of patients undergoing long spinal fusion according to bone density","volume":"106","author":"Mohanty","year":"2024","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"2026071419580404900_dgag092-B44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/BRS.0000000000004268","article-title":"Best practice guidelines for assessment and management of osteoporosis in adult patients undergoing elective spinal reconstruction","volume":"47","author":"Sardar","year":"2022","journal-title":"Spine (Phila Pa 1976)"},{"issue":"1","key":"2026071419580404900_dgag092-B45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11657-016-0296-x","article-title":"Orthopedic surgeons\u2019 attitudes to osteoporosis investigation and management after minimal trauma fracture (MTF)","volume":"12","author":"Anderson-Wurf","year":"2017","journal-title":"Arch Osteoporos"},{"issue":"1","key":"2026071419580404900_dgag092-B46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13018-019-1103-3","article-title":"Orthopedic surgeons\u2019 views on the osteoporosis care gap and potential solutions: survey results","volume":"14","author":"Barton","year":"2019","journal-title":"J Orthop Surg Res"},{"issue":"3","key":"2026071419580404900_dgag092-B47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjmed.2016.10.018","article-title":"Trends and disparities in osteoporosis screening among women in the United States, 2008-2014","volume":"130","author":"Gillespie","year":"2017","journal-title":"Am J Med"},{"issue":"4","key":"2026071419580404900_dgag092-B48","doi-asserted-by":"crossref","first-page":"e14308","DOI":"10.1111\/1475-6773.14308","article-title":"Restrictiveness of Medicare Advantage provider networks across physician specialties","volume":"59","author":"Feyman","year":"2024","journal-title":"Health Serv Res"},{"key":"2026071419580404900_dgag092-B49","doi-asserted-by":"crossref","first-page":"e077797","DOI":"10.1136\/bmj-2023-077797","article-title":"Schwartz AL. Comparison of prior authorization across insurers: cross sectional evidence from Medicare advantage","volume":"384","author":"Gupta","year":"2024","journal-title":"BMJ"},{"issue":"6","key":"2026071419580404900_dgag092-B50","doi-asserted-by":"crossref","first-page":"1089\u2013","DOI":"10.1007\/s00198-025-07484-3","article-title":"Osteoporosis medication use over time in the United States and Canada","volume":"36","author":"Hayes","year":"2025","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026071419580404900_dgag092-B51","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.2565","article-title":"Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996\u20132012: an ecological analysis","volume":"30","author":"Jha","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026071419580404900_dgag092-B52","first-page":"CD004523","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"5","author":"Wells","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2026071419580404900_dgag092-B53","first-page":"CD003376","article-title":"Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"2008","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2026071419580404900_dgag092-B54","first-page":"CD001155","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2026071419580404900_dgag092-B55","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0025-6196(11)61093-8","article-title":"Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis","volume":"82","author":"Kothawala","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2026071419580404900_dgag092-B56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 years of age","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag092\/67225408\/dgag092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/2320\/67225408\/dgag092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/2320\/67225408\/dgag092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:58:33Z","timestamp":1784073513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/8\/2320\/8505606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag092","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,4]]}}}